Abstract:Liver fibrosis refers to the process underlying the development of chronic liver diseases, wherein liver cells are repeatedly destroyed and regenerated, which leads to an excessive deposition and abnormal distribution of the extracellular matrix such as collagen, glycoprotein and proteoglycan in the liver. Liver fibrosis thus constitutes the pathological repair response of the liver to chronic injury. Hepatic fibrosis is a key step in the progression of chronic liver disease to cirrhosis and an important factor affecting the prognosis of chronic liver disease. Further development of liver fibrosis may lead to structural disorders of the liver, nodular regeneration of hepatocytes and the formation of cirrhosis. Hepatic fibrosis is histologically reversible if treated aggressively during this period, but when fibrosis progresses to the stage of cirrhosis, reversal is very difficult, resulting in a poor prognosis. There are many causes of liver fibrosis, including liver injury caused by drugs, viral hepatitis, alcoholic liver, fatty liver and autoimmune disease. The mechanism underlying hepatic fibrosis differs among etiologies. The establishment of an appropriate animal model of liver fibrosis is not only an important basis for the in-depth study of the pathogenesis of liver fibrosis but also an important means for clinical experts to select drugs for the prevention and treatment of liver fibrosis. The present study focused on the modeling methods and fibrosis characteristics of different animal models of liver fibrosis, such as a chemical-induced liver fibrosis model, autoimmune liver fibrosis model, cholestatic liver fibrosis model, alcoholic liver fibrosis model and non-alcoholic liver fibrosis model. In addition, we also summarize the research and application prospects concerning new organoids in liver fibrosis models proposed in recent years. A suitable animal model of liver fibrosis and organoid fibrosis model that closely resemble the physiological state of the human body will provide bases for the in-depth study of the pathogenesis of liver fibrosis and the development of therapeutic drugs.

Mice Hepatic Organoids for Modeling Nonalcoholic Fatty Liver Disease and Drug Response

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System

A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression

Human Liver Organoid: Modeling Liver Steatosis and Beyond

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Ginsenoside Rb1 Improves Human Nonalcoholic Fatty Liver Disease with Liver Organoids-on-a-chip

Liver Organoids: Established Tools for Disease Modeling and Drug Development

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment

Animal and Organoid Models of Liver Fibrosis

Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver

Comparison of Animal Models for the Study of Nonalcoholic Fatty Liver Disease

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

A Novel 3d Liver Organoid System for Elucidation of Hepatic Glucose Metabolism